Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer's disease, ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.